+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Viral Vectors Market by Vector Type (Adeno Associated Virus, Adenovirus, Lentivirus), Application (Cell Therapy, Gene Therapy, Research), Therapeutic Area, End User, Production Stage, Production Scale - Global Forecast 2025-2030- Product Image
Viral Vectors Market by Vector Type (Adeno Associated Virus, Adenovirus, Lentivirus), Application (Cell Therapy, Gene Therapy, Research), Therapeutic Area, End User, Production Stage, Production Scale - Global Forecast 2025-2030- Product Image
Sale

Viral Vectors Market by Vector Type (Adeno Associated Virus, Adenovirus, Lentivirus), Application (Cell Therapy, Gene Therapy, Research), Therapeutic Area, End User, Production Stage, Production Scale - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5666371
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The viral vectors market is rapidly transforming biopharmaceutical research and therapeutic development, driven by accelerating scientific innovation and evolving global regulation. Senior leaders in pharma, biotech, and research institutions are now leveraging these advanced delivery systems to advance the frontier of precision medicine, cell therapy, and engineered vaccines.

Market Snapshot: Viral Vectors Market

The Viral Vectors Market grew from USD 1.88 billion in 2024 to USD 2.16 billion in 2025. It is expected to continue growing at a CAGR of 14.19%, reaching USD 4.19 billion by 2030. Increasing demand across gene and cell therapies, improved vector engineering, and regulatory alignment are shaping a competitive landscape. Companies are scaling manufacturing capacity and forging global partnerships to address both advanced clinical-stage campaigns and commercial deployments. Ongoing developments in regulatory policy and tariff adjustments are prompting organizations to adapt sourcing strategies and invest in future-ready infrastructure.

Scope & Segmentation

  • Vector Type: Adeno Associated Virus (AAV2, AAV8, AAV9), Adenovirus, Lentivirus, Retrovirus
  • Application: Cell Therapy (Car T, Dendritic, TCR T), Gene Therapy (Ex Vivo, In Vivo), Research (Basic, Preclinical), Vaccine (Prophylactic, Therapeutic)
  • Therapeutic Area: Cardiovascular Disorders (Coronary, Peripheral Vascular), Infectious Disease (Bacterial, Viral), Neurological Disorders (Neurodegenerative, Neurodevelopmental), Oncology (Hematological, Solid Tumor), Rare Diseases (Monogenic)
  • End User: Biopharma Companies, Hospitals and Clinics, Research Institutes
  • Production Stage: Downstream (Filtration, Formulation, Purification via Chromatography, Ultracentrifugation), Upstream (Cell Expansion, Harvesting, Transfection)
  • Production Scale: Clinical (Phase I–III), Commercial (Full Scale)
  • Regional Coverage: Americas (key US states, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (multiple countries), Asia-Pacific (China, India, Japan, Australia, South Korea, others)
  • Leading Companies Profiled: Thermo Fisher Scientific, Lonza Group, Merck KGaA, Catalent, WuXi AppTec, Novasep Holding, Oxford BioMedica, AGC Biologics, Cobra Biologics, Viralgen S.L.

Key Takeaways for Senior Decision-Makers

  • Technological advancements in capsid engineering and viral backbone design are enhancing tissue targeting and vector safety, supporting clinical and commercial success.
  • Strategic alliances—pairing process expertise with gene editing technology—are allowing for faster pipelines and more specialized applications in oncology, neurology, and rare diseases.
  • Regulatory bodies have streamlined guidance around assay validation and long-term monitoring, easing clinical translation and market access across global regions.
  • Academic, industry, and CDMO collaborations are leveraging shared resources for more efficient vector production and supply chain agility, minimizing disruption from policy or logistical shifts.
  • Emerging regional centers in Asia-Pacific and Latin America are expanding biomanufacturing capacity and infrastructure, matched by local incentives to attract worldwide clinical projects.
  • Continuous process optimization—via modular, single-use bioreactor systems and analytics-driven design—positions organizations to quickly scale and adapt within shifting regulatory frameworks.

Tariff Impact on Supply Chains and Collaboration

The introduction of new United States tariffs in 2025 has raised costs for crucial supplies, particularly for raw materials and equipment in viral vector production. This has prompted major companies to consider localizing manufacturing and to renegotiate sourcing to boost resilience. Research consortia and academic groups are adapting by consolidating orders and seeking alternative suppliers in favorable markets. Enhanced inventory management and regionalized partnerships are helping to stabilize reagent supply, and modular production lines are gaining traction for their ability to absorb future tariff and economic pressures.

Methodology & Data Sources

This report’s insights are grounded in primary interviews with executives at biopharma firms, CDMOs, and academic centers, supplemented with data from regulatory filings, patent databases, and clinical trial registries. Quantitative analysis is validated through triangulated sourcing and rigorous cross-verification, ensuring accurate tracking of trends and market movements.

Why This Report Matters

  • Unlocks a comprehensive view of the viral vectors market, supporting strategic investment, M&A, and partnership decisions that drive long-term value.
  • Delivers actionable insights on segment dynamics, regulatory adaptation, and technology integration crucial for competitive advantage in gene and cell therapy pipelines.
  • Highlights risks and opportunities arising from policy changes, international trade, and evolving product development strategies.

Conclusion

Senior executives gain clarity into pivotal developments shaping the viral vectors market. Use these verified insights to guide innovation, strengthen collaborations, and future-proof supply chain and manufacturing strategies.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advancements in engineered adeno-associated virus capsids for targeted in vivo gene delivery
5.2. Expansion of continuous bioprocessing platforms to increase viral vector manufacturing capacity
5.3. Integration of single-use bioreactor technologies in scalable lentiviral vector production systems
5.4. Emerging synthetic biology approaches for tunable promoter control in viral vector gene expression
5.5. Strategic collaborations between CMOs and biotech firms to accelerate viral vector supply chain resilience
5.6. Regulatory harmonization initiatives addressing global clinical trial approval for viral vector therapies
5.7. Development of mRNA-encoding viral vectors for rapid vaccine response to novel infectious disease outbreaks
5.8. Implementation of advanced analytics and AI-driven process monitoring in viral vector purification workflows
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Viral Vectors Market, by Vector Type
8.1. Introduction
8.2. Adeno Associated Virus
8.2.1. AAV2
8.2.2. AAV8
8.2.3. AAV9
8.3. Adenovirus
8.4. Lentivirus
8.5. Retrovirus
9. Viral Vectors Market, by Application
9.1. Introduction
9.2. Cell Therapy
9.2.1. Car T
9.2.2. Dendritic
9.2.3. TCR T
9.3. Gene Therapy
9.3.1. Ex Vivo
9.3.2. In Vivo
9.4. Research
9.4.1. Basic Research
9.4.2. Preclinical Research
9.5. Vaccine
9.5.1. Prophylactic
9.5.2. Therapeutic
10. Viral Vectors Market, by Therapeutic Area
10.1. Introduction
10.2. Cardiovascular Disorders
10.2.1. Coronary
10.2.2. Peripheral Vascular
10.3. Infectious Disease
10.3.1. Bacterial
10.3.2. Viral
10.4. Neurological Disorders
10.4.1. Neurodegenerative
10.4.2. Neurodevelopmental
10.5. Oncology
10.5.1. Hematological
10.5.2. Solid Tumor
10.6. Rare Diseases
10.6.1. Monogenic
11. Viral Vectors Market, by End User
11.1. Introduction
11.2. Biopharma Companies
11.3. Hospitals And Clinics
11.4. Research Institutes
12. Viral Vectors Market, by Production Stage
12.1. Introduction
12.2. Downstream
12.2.1. Filtration
12.2.2. Formulation
12.2.3. Purification
12.2.3.1. Chromatography
12.2.3.2. Ultracentrifugation
12.3. Upstream
12.3.1. Cell Expansion
12.3.2. Harvesting
12.3.3. Transfection
13. Viral Vectors Market, by Production Scale
13.1. Introduction
13.2. Clinical
13.2.1. Phase I
13.2.2. Phase II
13.2.3. Phase III
13.3. Commercial
13.3.1. Full Scale
14. Americas Viral Vectors Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Viral Vectors Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Viral Vectors Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Thermo Fisher Scientific Inc.
17.3.2. Lonza Group AG
17.3.3. Merck KGaA
17.3.4. Catalent Inc.
17.3.5. WuXi AppTec Co., Ltd.
17.3.6. Novasep Holding SAS
17.3.7. Oxford BioMedica plc
17.3.8. AGC Biologics Inc.
17.3.9. Cobra Biologics Ltd.
17.3.10. Viralgen S.L.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. VIRAL VECTORS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL VIRAL VECTORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 10. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES VIRAL VECTORS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES VIRAL VECTORS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. VIRAL VECTORS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. VIRAL VECTORS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. VIRAL VECTORS MARKET: RESEARCHAI
FIGURE 28. VIRAL VECTORS MARKET: RESEARCHSTATISTICS
FIGURE 29. VIRAL VECTORS MARKET: RESEARCHCONTACTS
FIGURE 30. VIRAL VECTORS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. VIRAL VECTORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL VIRAL VECTORS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL VIRAL VECTORS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV2, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV2, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV8, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV8, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV9, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV9, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL VIRAL VECTORS MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL VIRAL VECTORS MARKET SIZE, BY LENTIVIRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL VIRAL VECTORS MARKET SIZE, BY CAR T, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL VIRAL VECTORS MARKET SIZE, BY CAR T, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL VIRAL VECTORS MARKET SIZE, BY DENDRITIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL VIRAL VECTORS MARKET SIZE, BY DENDRITIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL VIRAL VECTORS MARKET SIZE, BY TCR T, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL VIRAL VECTORS MARKET SIZE, BY TCR T, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL VIRAL VECTORS MARKET SIZE, BY EX VIVO, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL VIRAL VECTORS MARKET SIZE, BY EX VIVO, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL VIRAL VECTORS MARKET SIZE, BY IN VIVO, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL VIRAL VECTORS MARKET SIZE, BY IN VIVO, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL VIRAL VECTORS MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL VIRAL VECTORS MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL VIRAL VECTORS MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL VIRAL VECTORS MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL VIRAL VECTORS MARKET SIZE, BY CORONARY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL VIRAL VECTORS MARKET SIZE, BY CORONARY, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL VIRAL VECTORS MARKET SIZE, BY PERIPHERAL VASCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL VIRAL VECTORS MARKET SIZE, BY PERIPHERAL VASCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL VIRAL VECTORS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL VIRAL VECTORS MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL VIRAL VECTORS MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL VIRAL VECTORS MARKET SIZE, BY VIRAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEGENERATIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEGENERATIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEVELOPMENTAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEVELOPMENTAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL VIRAL VECTORS MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL VIRAL VECTORS MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL VIRAL VECTORS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL VIRAL VECTORS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL VIRAL VECTORS MARKET SIZE, BY MONOGENIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL VIRAL VECTORS MARKET SIZE, BY MONOGENIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL VIRAL VECTORS MARKET SIZE, BY BIOPHARMA COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL VIRAL VECTORS MARKET SIZE, BY BIOPHARMA COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL VIRAL VECTORS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL VIRAL VECTORS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL VIRAL VECTORS MARKET SIZE, BY FILTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL VIRAL VECTORS MARKET SIZE, BY FILTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL VIRAL VECTORS MARKET SIZE, BY FORMULATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL VIRAL VECTORS MARKET SIZE, BY FORMULATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL VIRAL VECTORS MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL VIRAL VECTORS MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL VIRAL VECTORS MARKET SIZE, BY ULTRACENTRIFUGATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL VIRAL VECTORS MARKET SIZE, BY ULTRACENTRIFUGATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL EXPANSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL EXPANSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL VIRAL VECTORS MARKET SIZE, BY HARVESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL VIRAL VECTORS MARKET SIZE, BY HARVESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL VIRAL VECTORS MARKET SIZE, BY TRANSFECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL VIRAL VECTORS MARKET SIZE, BY TRANSFECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL VIRAL VECTORS MARKET SIZE, BY CLINICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL VIRAL VECTORS MARKET SIZE, BY CLINICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 143. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE I, BY REGION, 2025-2030 (USD MILLION)
TABLE 145. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
TABLE 146. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE II, BY REGION, 2025-2030 (USD MILLION)
TABLE 147. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
TABLE 148. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE III, BY REGION, 2025-2030 (USD MILLION)
TABLE 149. GLOBAL VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 150. GLOBAL VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 151. GLOBAL VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 152. GLOBAL VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 153. GLOBAL VIRAL VECTORS MARKET SIZE, BY FULL SCALE, BY REGION, 2018-2024 (USD MILLION)
TABLE 154. GLOBAL VIRAL VECTORS MARKET SIZE, BY FULL SCALE, BY REGION, 2025-2030 (USD MILLION)
TABLE 155. GLOBAL VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2018-2024 (USD MILLION)
TABLE 156. GLOBAL VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2025-2030 (USD MILLION)
TABLE 169. AMERICAS VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2024 (USD MILLION)
TABLE 170. AMERICAS VIRAL VECTORS MARKET SIZE, BY VACCINE, 2025-2030 (USD MILLION)
TABLE 171. AMERICAS VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 172. AMERICAS VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 173. AMERICAS VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 174. AMERICAS VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 175. AMERICAS VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
TABLE 176. AMERICAS VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
TABLE 177. AMERICAS VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 178. AMERICAS VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 179. AMERICAS VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 180. AMERICAS VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 181. AMERICAS VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
TABLE 182. AMERICAS VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
TABLE 183. AMERICAS VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. AMERICAS VIRAL VECTORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. AMERICAS VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
TABLE 186. AMERICAS VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
TABLE 187. AMERICAS VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
TABLE 188. AMERICAS VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2025-2030 (USD MILLION)
TABLE 189. AMERICAS VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2024 (USD MILLION)
TABLE 190. AMERICAS VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2025-2030 (USD MILLION)
TABLE 191. AMERICAS VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
TABLE 192. AMERICAS VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2025-2030 (USD MILLION)
TABLE 193. AMERICAS VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
TABLE 194. AMERICAS VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2025-2030 (USD MILLION)
TABLE 195. AMERICAS VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 196. AMERICAS VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 197. AMERICAS VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2018-2024 (USD MILLION)
TABLE 198. AMERICAS VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2025-2030 (USD MILLION)
TABLE 199. AMERICAS VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 200. AMERICAS VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 203. UNITED STATES VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2024 (USD MILLION)
TABLE 204. UNITED STATES VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2025-2030 (USD MILLION)
TABLE 205. UNITED STATES VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 206. UNITED STATES VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 207. UNITED STATES VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 208. UNITED STATES VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 209. UNITED STATES VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 210. UNITED STATES VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 211. UNITED STATES VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
TABLE 212. UNITED STATES VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2025-2030 (USD MILLION)
TABLE 213. UNITED STATES VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2024 (USD MILLION)
TABLE 214. UNITED STATES VIRAL VECTORS MARKET SIZE, BY VACCINE, 2025-2030 (USD MILLION)
TABLE 215. UNITED STATES VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 216. UNITED STATES VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 217. UNITED STATES VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 218. UNITED STATES VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 219. UNITED STATES VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
TABLE 220. UNITED STATES VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
TABLE 221. UNITED STATES VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 222. UNITED STATES VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 223. UNITED STATES VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 224. UNITED STATES VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 225. UNITED STATES VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
TABLE 226. UNITED STATES VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
TABLE 227. UNITED STATES VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. UNITED STATES VIRAL VECTORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. UNITED STATES VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
TABLE 230. UNITED STATES VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
TABLE 231. UNITED STATES VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
TABLE 232. UNITED STATES VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2025-2030 (USD MILLION)
TABLE 233. UNITED STATES VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2024 (USD MILLION)
TABLE 234. UNITED STATES VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2025-2030 (USD MILLION)
TABLE 235. UNITED STATES VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
TABLE 236. UNITED STATES VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2025-2030 (USD MILLION)
TABLE 237. UNITED STATES VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
TABLE 238. UNITED STATES VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2025-2030 (USD MILLION)
TABLE 239. UNITED STATES VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 240. UNITED STATES VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 241. UNITED STATES VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2018-2024 (USD MILLION)
TABLE 242. UNITED STATES VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2025-2030 (USD MILLION)
TABLE 243. UNITED STATES VIRAL VECTORS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 244. UNITED STATES VIRAL VECTORS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 245. CANADA VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 246. CANADA VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 247. CANADA VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2024 (USD MILLION)
TABLE 248. CANADA VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2025-2030 (USD MILLION)
TABLE 249. CANADA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 250. CANADA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 251. CANADA VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 252. CANADA VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 253. CANADA VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 254. CANADA VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 255. CANADA VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
TABLE 256. CANADA VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2025-2030 (USD MILLION)
TABLE 257. CANADA VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2024 (USD MILLION)
TABLE 258. CANADA VIRAL VECTORS MARKET SIZE, BY VACCINE, 2025-2030 (USD MILLION)
TABLE 259. CANADA VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 260. CANADA VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 261. CANADA VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 262. CANADA VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 263. CANADA VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
TABLE 264. CANADA VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
TABLE 265. CANADA VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 266. CANADA VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 267. CANADA VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 268. CANADA VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 269. CANADA VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
TABLE 270. CANADA VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
TABLE 271. CANADA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. CANADA VIRAL VECTORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. CANADA VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
TABLE 274. CANADA VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
TABLE 275. CANADA VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
TABLE 276. CANADA VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2025-2030 (USD MILLION)
TABLE 277. CANADA VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2024 (USD MILLION)
TABLE 278. CANADA VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2025-2030 (USD MILLION)
TABLE 279. CANADA VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
TABLE 280. CANADA VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2025-2030 (USD MILLION)
TABLE 281. CANADA VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
TABLE 282. CANADA VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2025-2030 (USD MILLION)
TABLE 283. CANADA VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 284. CANADA VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 285. CANADA VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2018-2024 (USD MILLION)
TABLE 286. CANADA VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2025-2030 (USD MILLION)
TABLE 287. MEXICO VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 288. MEXICO VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 289. MEXICO VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2024 (USD MILLION)
TABLE 290. MEXICO VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2025-2030 (USD MILLION)
TABLE 291. MEXICO VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 292. MEXICO VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 293. MEXICO VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 294. MEXICO VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 295. MEXICO VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 296. MEXICO VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 297. MEXICO VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
TABLE 298. MEXICO VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2025-2030 (USD MILLION)
TABLE 299. MEXICO VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2024 (USD MILLION)
TABLE 300. MEXICO VIRAL VECTORS MARKET SIZE, BY VACCINE, 2025-2030 (USD MILLION)
TABLE 301. MEXICO VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 302. MEXICO VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 303. MEXICO VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 304. MEXICO VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 305. MEXICO VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
TABLE 306. MEXICO VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
TABLE 307. MEXICO VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 308. MEXICO VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 309. MEXICO VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 310. MEXICO VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 311. MEXICO VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
TABLE 312. MEXICO VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
TABLE 313. MEXICO VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 314. MEXICO VIRAL VECTORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 315. MEXICO VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
TABLE 316. MEXICO VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
TABLE 317. MEXICO VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
TABLE 318. MEXICO VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2025-2030 (USD MILLION)
TABLE 319. MEXICO VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2024 (USD MILLION)
TABLE 320. MEXICO VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2025-2030 (USD MILLION)
TABLE 321. MEXICO VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
TABLE 322. MEXICO VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2025-2030 (USD MILLION)
TABLE 323. MEXICO VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
TABLE 324. MEXICO VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2025-2030 (USD MILLION)
TABLE 325. MEXICO VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 326. MEXICO VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 327. MEXICO VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2018-2024 (USD MILLION)
TABLE 328. MEXICO VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2025-2030 (USD MILLION)
TABLE 329. BRAZIL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 330. BRAZIL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 331. BRAZIL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2024 (USD MILLION)
TABLE 332. BRAZIL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2025-2030 (USD MILLION)
TABLE 333. BRAZIL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 334. BRAZIL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 335. BRAZIL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 336. BRAZIL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 337. BRAZIL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 338. BRAZIL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 339. BRAZIL VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
TABLE 340. BRAZIL VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2025-2030 (USD MILLION)
TABLE 341. BRAZIL VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2024 (USD MILLION)
TABLE 342. BRAZIL VIRAL VECTORS MARKET SIZE, BY VACCINE, 2025-2030 (USD MILLION)
TABLE 343. BRAZIL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 344. BRAZIL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 345. BRAZIL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 346. BRAZIL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 347. BRAZIL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
TABLE 348. BRAZIL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
TABLE 349. BRAZIL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 350. BRAZIL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 351. BRAZIL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 352. BRAZIL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 353. BRAZIL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
TABLE 354. BRAZIL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
TABLE 355. BRAZIL VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 356. BRAZIL VIRAL VECTORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 357. BRAZIL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
TABLE 358. BRAZIL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
TABLE 359. BRAZIL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
TABLE 360. BRAZIL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2025-2030 (USD MILLION)
TABLE 361. BRAZIL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2024 (USD MILLION)
TABLE 362. BRAZIL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2025-2030 (USD MILLION)
TABLE 363. BRAZIL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
TABLE 364. BRAZIL VI

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Viral Vectors market report include:
  • Thermo Fisher Scientific Inc.
  • Lonza Group AG
  • Merck KGaA
  • Catalent Inc.
  • WuXi AppTec Co., Ltd.
  • Novasep Holding SAS
  • Oxford BioMedica plc
  • AGC Biologics Inc.
  • Cobra Biologics Ltd.
  • Viralgen S.L.

Table Information

Report AttributeDetails
No. of Pages184
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.16 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.19 Billion
Compound Annual Growth Rate14.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Gene Therapy Market by Vector Type (Non-Viral Vectors, Viral Vectors), Treatment Modality (Germline Therapy, Somatic Cell Therapy), Target Genome, Delivery Mode, Route of Administration, Patient Type, Therapeutic Area, End-User - Global Forecast 2025-2030 - Product Image

Gene Therapy Market by Vector Type (Non-Viral Vectors, Viral Vectors), Treatment Modality (Germline Therapy, Somatic Cell Therapy), Target Genome, Delivery Mode, Route of Administration, Patient Type, Therapeutic Area, End-User - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Cell & Gene Therapy Manufacturing Services Market by Service Type (Analytical & Quality Control Services, Cell Banking Services, Consulting Services), Technology Type (Gene Editing, Vectors), Therapeutic Area, Application, End-User - Global Forecast 2025-2030 - Product Image

Cell & Gene Therapy Manufacturing Services Market by Service Type (Analytical & Quality Control Services, Cell Banking Services, Consulting Services), Technology Type (Gene Editing, Vectors), Therapeutic Area, Application, End-User - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market Industry Trends and Global Forecasts to 2035, by Scale of Operation, Type of Vector, Application Area, Therapeutic Area, Type of Manufacturer and Geographical Region - Product Image

Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market Industry Trends and Global Forecasts to 2035, by Scale of Operation, Type of Vector, Application Area, Therapeutic Area, Type of Manufacturer and Geographical Region

  • Report
  • 768 Pages
  • Global
From
Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2025-2033 - Product Image

Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2025-2033

  • Report
  • 140 Pages
  • Global
From
Viral Vector Manufacturing - Global Strategic Business Report - Product Image

Viral Vector Manufacturing - Global Strategic Business Report

  • Report
  • 402 Pages
  • Global
From

About the Viral Vector Market

The Viral Vector market is a subset of the biotechnology industry that focuses on the development and production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, genetic disorders, and infectious diseases. Viral vectors are produced through a variety of methods, including recombinant DNA technology, synthetic biology, and cell-based systems. The production of viral vectors requires specialized equipment and expertise, making it a highly specialized field. The Viral Vector market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Novartis, Merck, Pfizer, AstraZeneca, and Sanofi. Additionally, there are a number of smaller companies that specialize in the production of viral vectors, such as Viralgen, Oxford BioMedica, and Vigene Biosciences. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.